RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function

Advances in Enzyme Regulation

Volumn 51, Issue 1, 2011, Pages 126-136

  Schäfer, Reinhold ^a   Sers, Christine ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL; EPIGENETICS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MICROARRAY ANALYSIS; ONCOGENE RAS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; EPIGENOMICS; GENE EXPRESSION PROFILING; GENES, RAS; HUMANS; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 79954474645     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2010.11.005     Document Type: Review

References (25)

1. Armeanu S., Bitzer M., Lauer U.M., Venturelli S., Pathil A., Krusch M., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65:6321-6329.
2. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., Van der Eb A.J., Vogelstein B. Prevalence of ras gene mutations in human colorectal tumors. Nature 1987, 327:293-297.
3. Cho K.R., Vogelstein B. Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem. 1992, (Suppl. 16G):137-141. 137-41.
4. Cui T., Leng F. Specific recognition of AT-rich DNA sequences by the mammalian high mobility group protein AT-hook 2: a SELEX study. Biochemistry 2007, 46:13059-13066.
5. Feinberg A.P., Vogelstein B. Alterations in DNA methylation in human colon neoplasia. Semin Surg Oncol 1987, 3:149-151.
6. Finkbeiner M.R., Astanehe A., To K., Fotovati A., Davies A.H., Zhao Y., et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009, 19(28):1421-1431.
7. Fritzmann J., Morkel M., Besser D., Budczies J., Kosel F., Brembeck F.H., et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009, 137:165-175.
8. Gazin C., Wajapeyee N., Gobeil S., Virbasius C.M., Green M.R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007, 449:1073-1077.
9. Gyorffy B., Schafer R. Biomarkers Downstream of RAS: a search for robust transcriptional targets. Curr. Cancer Drug Targets 2010 Aug 19, (Epub ahead of print).
10. Jürchott K.K.R, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kielbasa S.M, Ungethüm U, Lund P, Knösel T, Kemmner W, Morkel M, Fritzmann J, Schlag P.M, Birchmeier W, Krueger T, Sperling S, Sers C, Royer H.D, Herzel H.S.R. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genetics, in press.
11. Knosel T., Emde A., Schluns K., Chen Y., Jurchott K., Krause M., et al. Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 2005, 7:741-747.
12. Lund P., Weisshaupt K., Mikeska T., Jammas D., Chen X., Kuban R.J., et al. Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 2006, 25:4890-4903.
13. Malek A., Bakhidze E., Noske A., Sers C., Aigner A., Schäfer R., Tchernitsa O.I. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008, 123:348-356.
14. Narita M., Narita M., Krizhanovsky V., Nunez S., Chicas A., Hearn S.A., et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006, 126:503-514.
15. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001, 277:63-81.
16. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
17. Rhee I., Jair K.W., Yen R.W., Lengauer C., Herman J.G., Kinzler K.W., et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000, 404:1003-1007.
18. Schäfer R., Tchernitsa O.I., Sers C. Global effects of Ras signaling on the genetic program in mammalian cells. RAS family GTPases 2006, 169-198. Springer, Dordrecht. C.J. Der (Ed.).
19. Schulze A., Lehmann K., Jefferies H.B.J., McMahon M., Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001, 15:981-994.
20. Sers C., Kuner R., Falk C.S., Lund P., Sueltmann H., Braun M., et al. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 2009, 125:1626-1639.
21. Tchernitsa O.I., Sers C., Geflitter A., Schäfer R. Effects of Ras signaling on gene expression analyzed by customized microarrays. Methods in enzymology 2006, 373-387. C.J. Der, A. Hall, W.E. Balch (Eds.).
22. Tchernitsa O.I., Sers C., Zuber J., Hinzmann B., Grips M., Schramme A., et al. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 2004, 23:4536-4555.
23. Tullai J.W., Schaffer M.E., Mullenbrock S., Kasif S., Cooper G.M. Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways. J Biol Chem 2004, 279:20167-20177.
24. Tullai J.W., Schaffer M.E., Mullenbrock S., Sholder G., Kasif S., Cooper G.M. Immediate-early and delayed primary response genes are distinct in function and genomic architecture. J Biol Chem 2007, 282:23981-23995.
25. Zuber J., Tchernitsa O.I., Hinzmann B., Schmitz A.-C., Grips M., Hellriegel M., et al. A genome-wide survey of Ras transformation targets. Nat Genet 2000, 24:144-152.